SPR720 + Placebo + Open-label Standard of Care
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 17/100
17
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mycobacterium Avium Complex
Conditions
Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease
Trial Timeline
Dec 3, 2020 → Jan 28, 2021
NCT ID
NCT04553406About SPR720 + Placebo + Open-label Standard of Care
SPR720 + Placebo + Open-label Standard of Care is a phase 2 stage product being developed by Spero Therapeutics for Mycobacterium Avium Complex. The current trial status is terminated. This product is registered under clinical trial identifier NCT04553406. Target conditions include Mycobacterium Avium Complex, Non-tuberculous Mycobacterium Pulmonary Disease.
What happened to similar drugs?
3 of 8 similar drugs in Mycobacterium Avium Complex were approved
Approved (3) Terminated (1) Active (4)
Hype Score Breakdown
Clinical
12
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04553406 | Phase 2 | Terminated |
Competing Products
20 competing products in Mycobacterium Avium Complex